Edition:
United Kingdom

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

20.02USD
20 Jul 2018
Change (% chg)

$-0.04 (-0.20%)
Prev Close
$20.06
Open
$20.04
Day's High
$20.32
Day's Low
$19.99
Volume
176,698
Avg. Vol
428,530
52-wk High
$21.19
52-wk Low
$13.00

Latest Key Developments (Source: Significant Developments)

Ironwood Pharmaceuticals Determined Initial Organizational Designs Of Two New Businesses
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - DETERMINED INITIAL ORGANIZATIONAL DESIGNS OF TWO NEW BUSINESSES, INCLUDING EMPLOYEES' ROLES AND RESPONSIBILITIES.IRONWOOD PHARMACEUTICALS- AS PART OF INITIAL ORGANIZATIONAL DESIGNS PROCESS, CO COMMENCED IMPLEMENTATION OF REDUCTION IN WORKFORCE BY ABOUT 40 EMPLOYEES.IRONWOOD PHARMA - INITIAL ORGANIZATIONAL DESIGNS RELATED TO INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS.IRONWOOD PHARMACEUTICALS-ESTIMATES THAT IN CONNECTION WITH REDUCTION IN WORKFORCE TO INCUR CHARGES OF ABOUT $5.0 MILLION TO $5.5 MILLION.IRONWOOD PHARMACEUTICALS - EXPECTS TO SUBSTANTIALLY COMPLETE REDUCTION IN ITS WORKFORCE DURING YEAR ENDING DECEMBER 31, 2018.  Full Article

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article

Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017.IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​.IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017.IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017.  Full Article

Ironwood Pharmaceuticals Strengthens Executive Leadership Team
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM.IRONWOOD PHARMACEUTICALS INC - PROMOTED ‍ GINA CONSYLMAN TO SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.  Full Article

Ironwood Pharma files for potential mixed shelf offering
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Q3 non-GAAP loss per share $0.18.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals provides third quarter 2017 investor update.Q3 loss per share $0.22.Q3 revenue $87 million versus I/B/E/S view $73.6 million.Ironwood Pharmaceuticals Inc sees 2017 ‍R&D expenses to be in low-to-middle end of previously guided $145 million to $160 million range​.Ironwood Pharmaceuticals Inc - ‍data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017​.Ironwood Pharmaceuticals Inc - ‍to use less than $110 million in cash for operations in 2017, up from less than $100 million previously guided​.Ironwood - sees co & Allergan's ‍combined total 2017 marketing & sales expenses for Linzess in middle of previously guided $250 million to $280 million range​.Ironwood Pharmaceuticals Inc - co & Allergan no longer intend to pursue linaclotide delayed release-1​.  Full Article

Ironwood Pharma Q2 adj shr loss $0.16
Thursday, 4 Aug 2016 

Ironwood Pharmaceuticals Inc : Ironwood pharmaceuticals provides second quarter 2016 investor update . Q2 gaap loss per share $0.15 . Q2 revenue $54.4 million versus i/b/e/s view $55.5 million . Q2 non-gaap loss per share $0.16 . Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S . Allergan and ironwood continue to expect total 2016 marketing and sales expenses for linzess to be in range of $230 million to $260 million . Says continues to expect to use less than $70 million in cash for operations in 2016 . Q2 earnings per share view $-0.15, revenue view $55.5 million -- Thomson Reuters I/B/E/S Further company coverage: [IRWD.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION